Rent the Runway Inc vs Twist Bioscience Corp — how do they compare? Rent the Runway Inc trades at $1.71 (market cap $61.75M), while Twist Bioscience Corp trades at $162.24 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 163.2× Rent the Runway Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and Twist Bioscience Corp for 27 Days on average.
| RENT | TWST | |
|---|---|---|
Market Cap | $61.75M | $10.08B |
Volume | 193,323 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $205.00 |
52-Week Low | $1.55 | $25.45 |
Typical Hold Time | 56 Days | 27 Days |
Enterprise Value | $228.75M | $10.01B |
Signals from Pluang's Aura AI — not financial advice
RENT trades at $1.765, up 5.06% today, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported revenue of $306.20M in 2025 with improving net loss margins, yet negative shareholder equity and high debt-to-asset ratios persist. Recent news includes a CEO appointment and multiple law firm investigations into investor claims, creating a complex sentiment backdrop.
The outlook remains challenged by financial instability and legal scrutiny, though analyst consensus leans buy with no sell ratings. Key risks include high leverage and ongoing losses, while potential upside hinges on execution of growth initiatives and margin improvement. Investors face significant volatility amid restructuring efforts.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →